4D Molecular Therapeutics
FDMT
64 hedge funds and large institutions have $665M invested in 4D Molecular Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
75% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 16
23% more funds holding
Funds holding: 52 → 64 (+12)
10% more capital invested
Capital invested by funds: $602M → $665M (+$62.2M)
2.55% more ownership
Funds ownership: 55.09% → 57.64% (+2.6%)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$24M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.9M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$12.4M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$9.67M |
| 5 |
CC
Casdin Capital
New York
|
+$9.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$16.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.88M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.27M |
| 5 |
O
OrbiMed
New York
|
-$5.18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EGM
76
Engineers Gate Manager
New York
| – | -$337K | -8,139 | Closed |
|
|
MS
77
Maven Securities
St Helier,
Jersey
| – | -$271K | -6,500 | Closed |
|
|
SAM
78
Sectoral Asset Management
Montreal,
Quebec, Canada
| – | -$217K | -5,224 | Closed |
|
79
Norges Bank
Oslo,
Norway
| – | -$207K | -5,000 | Closed |
|
|
DKCM
80
Davidson Kempner Capital Management
New York
| – | -$124K | -3,000 | Closed |
|
FDMT Hedge Fund Activity: Q1 2021 in Review
64 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2021, worth a combined $665M — up 10% from $602M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new FDMT positions and 16 closed out — a net gain of 12 holders — while 13 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $24M. The largest seller was SB Management, cutting an estimated $16.4M.
- 64 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2021, up from 52 in Q4 2020.
- Funds reported $665M of 4D Molecular Therapeutics stock for Q1 2021, up 10% quarter-over-quarter.
- 28 funds opened new 4D Molecular Therapeutics positions in Q1 2021 and 16 closed out, a net change of +12 holders.
- The largest 4D Molecular Therapeutics buyer in Q1 2021 was BlackRock, an estimated $24M added.
- The largest 4D Molecular Therapeutics seller in Q1 2021 was SB Management, an estimated $16.4M sold.
Based on aggregated 13F filings for Q1 2021.